|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007102,
umls-concept:C0016343,
umls-concept:C0016360,
umls-concept:C0023413,
umls-concept:C0023556,
umls-concept:C0032790,
umls-concept:C0035647,
umls-concept:C0205253,
umls-concept:C0205373,
umls-concept:C0442120,
umls-concept:C0728940,
umls-concept:C0920321
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
1994-10-27
|
|
pubmed:abstractText |
The purpose of this study was to evaluate the toxicity of immediate postoperative intraperitoneal (IP) floxuridine (FUdR) and leucovorin (LV) after resection of high risk colon cancer, and to determine the appropriate dose of intravenous fluorouracil (FU) plus levamisole during concurrent intraperitoneal therapy.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
74
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2224-33
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:7922973-Adult,
pubmed-meshheading:7922973-Aged,
pubmed-meshheading:7922973-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7922973-Colonic Neoplasms,
pubmed-meshheading:7922973-Combined Modality Therapy,
pubmed-meshheading:7922973-Female,
pubmed-meshheading:7922973-Floxuridine,
pubmed-meshheading:7922973-Fluorouracil,
pubmed-meshheading:7922973-Humans,
pubmed-meshheading:7922973-Infusions, Parenteral,
pubmed-meshheading:7922973-Leucovorin,
pubmed-meshheading:7922973-Levamisole,
pubmed-meshheading:7922973-Male,
pubmed-meshheading:7922973-Middle Aged,
pubmed-meshheading:7922973-Neoplasm Recurrence, Local,
pubmed-meshheading:7922973-Postoperative Period,
pubmed-meshheading:7922973-Survival Analysis
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer.
|
|
pubmed:affiliation |
Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase I
|
